Second Phase 3 study of ZX008 in Dravet's met primary and all key second endpoints. Data for ZX008 in Dravet continues to look very good with no signs of cardiac issues seen when this drug was previously used (at higher doses) as an appetite suppressant. This continues to look very approvable based on both Ph3 trials, including this trial with standard of care in Europe - stiripentol. Stock up ~33% in 2 days after report out.
Congrats to ZGNX on More Positive Data